Scinai Immunotherapeutics (SCNI) Capital Expenditures Growth (3y) (2021 - 2026)
Scinai Immunotherapeutics (SCNI) Capital Expenditures Growth (3y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | - |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.62 Bn | 466.83 Bn | 1.35 Bn | -12.25% |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn | 46.88% |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn | 8.97% |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.75 Bn | 50.57 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 16.27% |
| 10 | Scinai Immunotherapeutics | 3.74 Bn | 627.11 Mn | -1.12 Mn | 20.63% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.63% |
| Jun 30, 2025 | 59.15% |
| Mar 31, 2025 | -26.35% |
| Dec 31, 2024 | -48.91% |
| Sep 30, 2024 | 0.00% |
| Jun 30, 2024 | 61.60% |
| Mar 31, 2024 | 34.14% |
| Dec 31, 2023 | 133.44% |
| Sep 30, 2023 | 81.86% |
| Jun 30, 2023 | 34.06% |
| Dec 31, 2022 | 34.12% |
| Sep 30, 2022 | 66.69% |
| Mar 31, 2022 | 37.38% |
| Mar 31, 2021 | 84.92% |